Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Cartesian Therapeutics in a report issued on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($7.10) for the year. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($0.30) by ($2.10). The firm had revenue of $8.27 million for the quarter. Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%.

Several other equities research analysts have also commented on the company. HC Wainwright boosted their price target on Cartesian Therapeutics from $2.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC assumed coverage on Cartesian Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $42.00 target price on the stock. Finally, SVB Leerink assumed coverage on Cartesian Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $39.00 target price on the stock.

Cartesian Therapeutics Stock Performance

Shares of NASDAQ:RNAC opened at $20.72 on Wednesday. The stock’s 50 day moving average price is $19.29. Cartesian Therapeutics has a 12 month low of $11.66 and a 12 month high of $42.60.

Insiders Place Their Bets

In other Cartesian Therapeutics news, Director Timothy A. Springer purchased 21,612 shares of Cartesian Therapeutics stock in a transaction on Thursday, March 14th. The shares were bought at an average price of $16.20 per share, with a total value of $350,114.40. Following the purchase, the director now directly owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired a total of 22,472 shares of company stock valued at $365,981 in the last quarter. 31.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee acquired a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned about 0.98% of Cartesian Therapeutics as of its most recent SEC filing. 86.95% of the stock is currently owned by institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.